Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
| Autor: | Zhang, Pin *, Sun, Tao *, Zhang, Qingyuan *, Yuan, Zhongyu, Jiang, Zefei, Wang, Xiao Jia, Cui, Shude, Teng, Yuee, Hu, Xi-Chun, Yang, Junlan, Pan, Hongming, Tong, Zhongsheng, Li, Huiping, Yao, Qiang, Wang, Yongsheng, Yin, Yongmei, Sun, Ping, Zheng, Hong, Cheng, Jing, Lu, Jinsong, Zhang, Baochun, Geng, Cuizhi, Liu, Jian, Peng, Roujun, Yan, Min, Zhang, Shaohua, Huang, Jian, Tang, Li, Qiu, Rongguo, Xu, Binghe * |
|---|---|
| Zdroj: | In The Lancet Oncology March 2017 18(3):371-383 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|